KalshiVérifier la disponibilitéKYC requis2% de fraisDonnées de résolution vérifiéesGrossièrement calibréProbabilité implicite actuelleBefore September 24%-2.0%En tête parmi 4 options
Qualite du marche
80 / 100
Haute qualitéVolume 24h
1,3 k €
Liquidité
27,5 k €
Liquidité élevéeAchat / Vente
24.0% / 25.0%
Spread
4.2%
Spread modéréDonnées du marché
Mis à jour il y a 18 minutes
24 mars 26, 14:001 sept. 26, 3:59
Tendances
Fonds fictifs uniquement, aucun argent réelCeci n'est pas un conseil financier
Résultat choisi
Before September24%
Tendance du volume
$1.5k2 juil.25j de données26 juil.
Marchés Associés
New pandemic in 2026?
6,2 k €Oui: 7%
POLYMARKET
POLYMARKET
Measles cases in 2026?
2,5 k €Above 4000: 39%KALSHI
KALSHI
Hantavirus pandemic in 2026?
2,2 k €Oui: 3%POLYMARKET
POLYMARKET
Ebola pandemic in 2026?
1,7 k €Oui: 4%POLYMARKET
POLYMARKET
When "Will Masking Return"? (widespread mask mandates in the USA)
996,3 €September 2023: 1%MANIFOLD MARKETS
MANIFOLD MARKETSWill the NIH indirect cost cap stick?
879,1 €Oui: 11.4%MANIFOLD MARKETS
MANIFOLD MARKETSActifs dans ces sujets
Règles
If the FDA announces Reclassification of BPC-157 to Category 1 of the Bulk Drug Substances List before Jul 1, 2026, then the market resolves to Yes.
- The Payout Criterion is satisfied by placement of BPC-157 in either Category 1 or Category 1 Bulk Drug Substances Under Evaluation on the 503A Bulk Drug Substances list, as either designation restores compounding eligibility.
- Removal from Category 2 alone, without placement in Category 1, does not satisfy the Payout Criterion.
- If the FDA announces Reclassification of BPC-157 to Category 1 of the Bulk Drug Substances List before Sep 1, 2026, then the market resolves to Yes.
- If the FDA announces Reclassification of BPC-157 to Category 1 of the Bulk Drug Substances List before Nov 1, 2026, then the market resolves to Yes.
- If the FDA announces Reclassification of BPC-157 to Category 1 of the Bulk Drug Substances List before Jan 1, 2027, then the market resolves to Yes.